Skip to main content

Advertisement

Inflammatory processes and elevated osteoclast activity chaperon atrophic non-union establishment in a murine model

Abstract

Background

Delayed bone healing, especially in long bones poses one of the biggest problems in orthopeadic and reconstructive surgery and causes tremendous costs every year. There is a need for exploring the causes in order to find an adequate therapy. Earlier investigations of human scaphoid non-union revealed an elevated osteoclast activity, accompanied by upregulated levels of TGF-beta and RANKL. Interestingly, scaphoid non-union seemed to be well vascularized.

Methods

In the current study, we used a murine femur-defect model to study atrophic non unions over a time-course of 10 weeks. Different time points were chosen, to gather insights into the dynamic processes of non-union establishment.

Results

Histological analyses as well as western blots and qRT-PCR indicated enhanced osteoclast activity throughout the observation period, paralleled by elevated levels of TGF-beta, TNF-alpha, MMP9, MMP13 and RANKL, especially during the early phases of non-union establishment. Interestingly, elevated levels of these mediators decreased markedly over a period of 10 weeks, as inflammatory reaction during non-union establishment seemed to wear out. To our surprise, osteoblastogenesis seemed to be unaffected during early stages of non-union establishment.

Conclusion

Taken together, we gained first insights into the establishment process of atrophic non unions, in which inflammatory processes accompanied by highly elevated osteoclast activity seem to play a leading role.

Background

Although bone regeneration is a reliable process, fracture healing is often accompanied with a variety of complications. One of the most common problems is non-union establishment after a delayed healing period [1]. For instance, the rate of non-unions after open tibial fractures is considered around 17% [2]. Non-unions can be defined as either atrophic or hypertrophic based on radiological aspects [3]. While hypertrophic non-unions constitute normal callus tissue without bony bridging, atrophic non-unions show no relevant callus tissue. Furthermore, hypertrophic non-unions are mostly caused by a lack of fracture stability, while causes for atrophic non-unions are quite diverse [1]. There are several risk factors that contribute to atrophic non-union, such as gender, age, diabetes, osteoporosis, smoking and NSAIDs [4]. However, surprisingly little is known about their exact causes [4,5,6]. Novel therapies like extracorporal shock wave therapy could show improvement targeting hypertrophic non-unions, but are less effective for atrophic non-unions [7]. For instance, it was proposed that impaired vascularization is a critical key factor for delayed bone healing [8]. Previously, an avascular fracture site was contemplated to be causative for atrophic non-union establishment [9, 10]. This hypothesis was maintained by different authors, who could demonstrate impaired fracture healing by virtue of inhibiting angiogenesis during fracture healing in animal models [11,12,13]. Conversely, stimulation of angiogenesis could improve impaired fracture healing [14,15,16]. In contrast to these findings, other authors showed that atrophic non-unions seem to be well vascularized [17,18,19,20]. In a murine animal model, Garcia et al. [21] observed no difference in vessel density and increased levels of VEGF-A in the non-union group at early and late time points upon atrophic non-union establishment. Accordingly, in our own work we could find human scaphoid non-unions to be well vascularized. Summarized, the exact role of angiogenesis in atrophic non-union establishment is still subject to debate.

Additional research focused on the role of BMPs and other factors critical for bone regeneration or atrophic non-union establishment [22,23,24,25].

Thus, reasons for atrophic non-union establishment still remain unclear and inflammatory processes with resulting osteoclastogenesis have not been investigated in detail.

Recent data from our investigation on established human atrophic scaphoid non-unions revealed that gene-expression of TGF-β, Wnt 5a and RANKL were significantly upregulated as compared to healthy bone tissue [21]. To our surprise, results of this study showed that inflammatory processes and subsequently osteoclastogenesis could play a key role.

Even though human data can be considered ideal when tackling such an important problem, the fact that we were restricted to analyze specimens of constituted non-unions left us with an unsolved problem: exploring mechanisms and dynamics that contribute to atrophic non-union establishment in this setting is unfeasible. Therefore, the study presented here approached this paucity and provided a unique opportunity to translate the results we obtained from human samples into an animal model. As the dynamic processes of non-union establishment are more or less unclear, this study aimed to reveal them in an established murine model of atrophic non-unions.

Therefore, we adapted an existing murine animal model, generating an atrophic non-union in mouse femur [26].

Methods

Surgical procedure

12 week old C57BL/6J male and female mice with an average weight of 25 g were used for this project. Surgical steps were performed, as previously described [26].

In preparation of surgical procedure, the right leg was shaved and disinfected. A 4 mm medial parapatellar incision was placed and the patella was dislocated laterally. Then a 0.5 mm hole was drilled into the intracondylar notch of the femur and a distally flattened 24G needle was implanted intramedullary into the right femur of the animal. Then the implanted pin was flattened at the distal end to prevent secondary pin loss. Then the patella was replaced and the wound was closed. After implantation of the pin a second incision was made in the middle of the lateral thigh. The musculus quadriceps was lateralized and the femur was exposed. Afterwards, a custom-made clip of 6 mm length was implanted into the ventro-dorsal femur. Then an osteotomy with a gap size of 1.8 mm was created in the non-union group with a fine drilling device [proxxon micromot 50, proxxon, Trier (Germany)] between the metallic clip using size-standardized spherical trephines under permanent saline cooling to prevent thermal damage around the defect site. In the control group a gap size of 0.25 mm was created accordingly with a Gigli saw [Gigli saw wire, 0,25 mm, AO Research Institute, Davos (Switzerland)]. The small gap size of 0.25 mm in the control group was mimicking physiological bone regeneration after bone fractures. The metallic clip inserted before guaranteed maintenance of the gap size. The gap sizes was controlled by custom-made template of 1.8 mm. The periosteum of the fracture site was left intact. Afterwards the wound was closed.

Histology, immunohistochemistry and histomorphometry

Data presented are a representative of at least three independent experiments.

At the indicated time points (48 h and 1, 5, 10 weeks) femora of six animals per group were harvested, the metallic pin and clip removed and fixed in 4% paraformaldehyde overnight, decalcified in 19% EDTA and paraffin embedded. Femora were then longitudinally sectioned at 9 µm on a Microtome. Tartrate-resistant acid phosphatase (TRAP) staining, which is a reliable marker detecting mature osteoclasts, was performed with TRAP Kit (Sigma-Aldrich, St. Louis, USA) after manufacturers instruction.

Additionally, immunohistochemical staining with primary antibodies against Osteocalcin and PCNA (Santa Cruz Biotechnologies, Dallas, USA) were performed using Vectastain ABC Kit (Vector Laboratories, Burlingame, USA). After deparaffinization and rehydration, specimens were incubated with Proteinase K for antigen demasking. Endogenous peroxidase activity was quenched by incubation with 3% hydrogen peroxide solution. Thereafter, specimens were blocked with normal blocking serum to prevent unspecific binding of primary antibody that was subsequently applicated and incubated overnight at 4 °C. Following, secondary antibody conjugated to horseradish peroxidase (HRP) was used and staining reaction was performed by use of NovaRED (HRP) Peroxidase Substrate Kit (Vector Laboratories, Burlingame, USA).

For immunofluorescent staining, primary antibody against RUNX2 (Santa Cruz Biotechnologies, Dallas, USA) was used. Initial steps were carried out similar to immunohistochemical staining until application of primary antibody. Thereafter, samples were incubated with secondary antibody conjugated to Alexa Fluor594 (Thermo Fisher Scientific, Waltham, USA). Images were taken with Zeiss Axioplan microscope.

Histomorphometry of immunohistochemical staining was performed with Photoshop (Adobe, San Jose, USA). Pixels were counted semiautomatically using the magic wand tool (tolerance 60, noncontiguous).

RNA isolation and gene expression analysis

For RNA isolation, femoral defects of four animals per group were homogenized and RNeasy mini kit was used according to the manufacturer’s instruction (Qiagen, Hilden, Germany). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using TaqMan probes in StepOnePlus (Applied Biosystems, Foster City, USA) performed in triplicates. Expression data was normalized with housekeeping genes (Gapdh and 18S) and calculated with the ∆Ct method. Genes examined were osteogenesis-related genes TGF-β, Runx2, and osteoclastogenesis-related genes RANKL, OPG and DCSTAMP. Moreover, inflammation-related genes TNF-α, MMP 9, 13 were analyzed. Primer sequences have been obtained with Primer-Blast (NIH).

Western Blot analysis

Isolated protein of 6 animals per group was combined and mixed with Laemmli sample buffer. After denaturation at 95 °C, samples were kept on ice until loading of the SDS PAGE. 15% polyacrylamide gels were used for electrophoresis of 30 µg total protein per lane. Protein was transferred to a nitrocellulose membrane using wet transfer method before membranes were blocked with 3% bovine serum albumin to prevent unspecific binding. After washing, membranes were incubated with primary antibodies RANKL, Runx2, TNF-α, TGF-β and MMP13 (Abcam, Cambridge, UK) overnight at 4 °C, followed by washing and incubation with HRP-conjugated secondary antibody (Thermo Fisher Scientific, Waltham, USA; Santa Cruz Biotechnologies, Dallas, USA). Proteins were detected for 30–60 s by enhanced chemoluminescence.

Statistics

Results are presented as mean ± standard error of the mean (SEM), while p-values were calculated by student’s t-test comparing two groups and ANOVA comparing more than two groups. Tukey’s test was used for post hoc comparisons. Statistical significances were set at a p-value < 0.05.

Results

Osteoblast and osteoclast function during non-union establishment

Our primary interest investigating the reasons for non-union establishment was to evaluate osteoblast and osteoclast function and reveal dysregulated bone homeostasis of formation and resorption. Osteoblastogenesis evaluated in runt-related transcription factor 2 (Runx2) staining, gene expression analysis and western blot showed significant downregulation at 48 h, 5 weeks and 10 weeks, compared to control group (Figs. 1, 2, 3). Mature osteoblasts detected by osteocalcin staining were significantly diminished in the non-union group at 5 and 10 weeks (Fig. 1).

Fig. 1
figure1

Osteoblasts are unaltered at early non-union establishment. Immunoflourescent stainings against Runx2 and Osteocalcin of non-union and control. Surprisingly, stainings evaluating osteoblastogenesis (Runx2) and osteoblast maturation (osteocalcin) revealed an unaltered osteoblast function at early non-union establishment processes, ranging 1 week after surgery. However, Runx2 and Osteocalcin stainings showed less signaling at 48 h and 5 and 10 weeks, indicating reduced osteoblasts at this time points. Scale bar represents 100 µm; p-value: *< 0.05

Fig. 2
figure2

Inflammatory mediators contribute to non-union establishment. QRT-PCR of osteogenesis-related genes Runx2, TGF-β, osteoclastogenesis-related genes RANKL, OPG and Dcstamp and inflammatory markers TNF-α, MMP9 and MMP13. According to stainings, Runx2 levels are only impaired at early fracture healing. Interestingly, while RANKL levels are elevated throughout non-union establishment, OPG expression seems to be elevated to physiological levels of fracture healing, except for established non-union after 10 weeks. Surprisingly, low levels of Dcstamp, important for osteoclast fusion, were detected in non-union and control except for the first week after surgery, indicating excessive osteoclast formation. Inflammatory markers TNF-α, MMP9 and MMP13 as well as TGF-β showed to be enhanced 1 and 5 weeks after surgery. p-value: *< 0.05

Fig. 3
figure3

Western blot verifies inflammatory reaction during non-union establishment. Western blots against Runx2, TNF-α, MMP13, RANKL and TGF-β. According to qRT-PCR results protein levels of Runx2 in non-unions seemed to be similar to control, except for early fracture healing, indicating a physiological osteoblastogenesis during non-union establishment. Moreover, RANKL mediated Osteoclast activity seemed to be upregulated during the whole non-union establishment process. This was accompanied by an inflammatory reaction, including TNF-α, MMP13 and TGF-β as central mediators. p-value: *< 0.05; ** < 0.01; ***< 0.001

Osteoclast number, which could be measured in TRAP staining, was highly elevated throughout the whole observation period in non-unions (Fig. 4). Interestingly, cell proliferation levels state, that the two groups were equal at all time points, seen in proliferating cell nuclear antigen (PCNA) staining (Fig. 4).

Fig. 4
figure4

Elevated osteoclast activity in non-unions comes with high proliferative activity. Immunohistochemical staining with primary antibody against PCNA and TRAP-staining. Elevated RANKL levels in non-unions, which could be seen in qRT-PCR and western blots lead to excessive osteoclast activity, spotted in TRAP-stainings. Interestingly, cell proliferation in non-unions evaluated by PCNA stainings was highly activated just similar to control animals. Scale bar represents 100 µm; p-value: *< 0.05; **< 0.01; ***< 0.001

Elevated cytokine levels in non-union establishment reveal an inflammatory reaction

Non-union establishment appeared to undergo an inflammatory reaction which was mediated by several cytokines. Levels of transforming growth factor β (TGF-β), tumor necrosis factor α (TNF-α), matrix metallopeptidase 9 (MMP9) and MMP13 showed to be increased after 1 and 5 weeks in non-union group validated in qRT PCR and Western Blot (Figs. 2 and 3).

Osteoclast activity is elevated via RANKL/OPG-axis

According to elevated osteoclast activity, levels of RANKL were upregulated in qRT-PCR and western blots throughout observation period, except for 48 h (see Figs. 2 and 3). Interestingly, in non-unions osteoprotegerin (OPG), a well-known decoy receptor for RANKL, showed comparable levels to control till 10 weeks after surgery, when OPG levels dropped markedly in non-unions. Moreover, dendrocyte expressed seven transmembrane protein (Dcstamp), important for osteoclastogenesis was highly elevated in non-unions 1 week after surgery.

Discussion

We observed upregulated levels of RANKL consistent with elevated osteoclast activity at all time points analysed in our murine model of non-union establishment. Levels of TGF-β, TNF-α and MMP13 were also upregulated one and 5 weeks after surgery and subsequently seemed to have important regulatory functions in this context.

The findings of this study have identified a number of different molecular targets, which may be useful for future research and novel therapeutic approaches for preventing delayed bone healing and non-union.

Interestingly, investigating the bone homeostasis of bone formation and resorption, we observed a physiological osteoblastogenesis during the early stages of fracture healing in the non-union model. However, in established non-unions, 10 weeks after surgery, osteoblasts were markedly downregulated. Consistent to this finding, cell proliferation was comparable to control, indicating non-union establishment as a highly active process.

It is well accepted that osteoblast function is impaired in established atrophic non-unions [27]. However, the fact that non-unions display a physiological osteoblastogenesis during early non-union establishment seemed striking. Thus, the unaffected bone formation seemed not to have the capability to overcome elevated bone resorption in non-union establishment as RANKL-mediated osteoclast activity was highly increased during the whole process. Continuative exploration of the exact regulation of osteoclasts, the leading role of RANKL/OPG-axis became evident during our studies. OPG is the main antagonist to osteoclast-activating RANKL [28]. Although it seemed striking that OPG levels in non-unions after 10 weeks dropped markedly with an exaggerated fold change between non-unions and control we assume a compensatory mechanism against upregulated RANKL during non-union establishment. Accordingly, dendrocyte expressed seven transmembrane protein (DC-STAMP) which is essential for osteoclast fusion and maturation [29] was enhanced during non-union establishment.

Consistent to our findings, Lienau et al. [24] observed unaltered expression levels of Runx2 during early fracture healing in a sheep osteotomy model mimicking delayed bone healing. Moreover, excessive osteoclast activity as a substantial part of non-union establishment could already be shown in animal and human studies [21, 24, 30].

Besides elucidating the homeostasis of bone formation and resorption processes, we further emphasized to characterize the role of inflammatory agents in non-unions. Selected factors which appeared to have a major impact on non-union establishment are TNF-α, TGF-β, MMP9 and MMP13.

Interestingly, both TNF-α and TGF-β had beneficial effects on fracture healing at early stages promoting osteogenesis and osteoblastogenesis [31,32,33]. However, studies in the field of osteoimmunology have revealed that chronic inflammation accompanied and mediated by upregulation of TNF-α lead to delayed bone regeneration and to an increased bone destruction by increasing osteoclast activity [34,35,36,37]. Additionally, in other chronic diseases like diabetes mellitus, delayed bone healing correlated with elevated levels of TNF-α, RANKL and high osteoclast activity [38]. Investigations in the field of Rheumatoid Arthritis and other degenerative bone diseases describe a special role for TNF-α in the interplay of bone destruction upon chronic inflammation [39,40,41]. In this context, common treatment strategies involving modulation of TNF-α proved to be quite effective against bone resorption in rheumatoid arthritis [42].

Moreover, enhanced expression of TGF-β lead to sustained differentiation of fibroblasts and could thereby dense persisting fibrous tissue in the fracture gap [43]. Accordingly, investigations of serum from patients suffering from atrophic non-unions showed enhanced levels of TGF-β [44]. Furthermore, enhanced levels of TGF-β could stimulate MMP13 expression in osteoblasts in vitro [45] and TGF-β-stimulated MMP13 expression seemed to be involved in the pathogenesis of osteoarthritis [46].

In fact, regarding MMP9 and MMP13 a dual role in fracture healing is evident. On the one hand, both factors are crucial for cartilage resorption during physiological bone regeneration, while knockout models of MMP9 and 13 showed delayed fracture healing [47, 48]. On the other hand, overexpression of MMP13 seems to be involved in different bone resorbing diseases like osteoarthritis [46] and formation of osteolytic lesions due to multiple myeloma [49] and breast cancer [50].

Conclusions

In summary, this novel data provides encouraging insights into the establishment of atrophic non-union. Interestingly, we could show bone resorption and elevated osteoclast activity may play an important role in non-union establishment. Furthermore, we identified numerous inflammatory agents; further studies testing new treatment strategies are under way. These studies may provide effective therapeutic approaches that prevent non-union establishment in the future.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

VEGF-A:

vascular endothelial growth factor A

BMP:

bone morphogenetic protein

TGF-β:

transforming growth factor beta

RANKL:

receptor activator of NF-κB ligand

OPG:

osteoprotegerin

Runx 2:

runt-related transcription factor 2

PCNA:

proliferating-cell-nuclear-antigen

TNF-α:

tumor necrosis factor alpha

DCSTAMP:

dendrocyte expressed seven transmembrane protein

MMP:

matrix metallopeptidase

References

  1. 1.

    Hak DJ, Fitzpatrick D, Bishop JA, Marsh JL, Tilp S, Schnettler R, Simpson H, Alt V. Delayed union and nonunions: epidemiology, clinical issues, and financial aspects. Injury. 2014;45(Suppl 2):S3–7.

  2. 2.

    Yusof NM, Khalid KA, Zulkifly AH, Zakaria Z, Amin MAM, Awang MS, Ahmad AC, Akter SFU. Factors associated with the outcome of open tibial fractures. MJMS. 2013;20:47–53.

  3. 3.

    Weber BG. Classification of pseudo-arthroses from a morphological and clinical point of view. Z Orthop. 1982;120:528–31.

  4. 4.

    Calori GM, Albisetti W, Agus A, Iori S, Tagliabue L. Risk factors contributing to fracture non-unions. Injury Int J Care Injured. 2007;385:511–8.

  5. 5.

    Dimitriou R, Carr IM, West RM, Markham AF, Giannoudis PV. Genetic predisposition to fracture non-union: a case control study of a preliminary single nucleotide polymorphisms analysis of the BMP pathway. BMC Musculoskelet Disord. 2011;12:44.

  6. 6.

    Xu J, Zhang C. SONG W: screening of differentially expressed genes associated with non-union skeletal fractures and analysis with a DNA microarray. Exp Ther Med. 2014;7:609–14.

  7. 7.

    Zelle BA, Gollwitzer H, Zlowodzki M, Bühren V. Extracorporeal shock wave therapy: current evidence. J Orthop Trauma. 2010;24:66–70.

  8. 8.

    Lu C, Miclau T, Hu D, Marcucio R. Ischemia leads to delayed union during fracture healing: a mouse model. J Orthop Res. 2006;25:51–61.

  9. 9.

    Paley D, Catagni MA, Argnani F, Villa A, Benedetti GB, Cattaneo R. Ilizarov treatment of tibia1 nonunions with bone loss. Clin Orthop Rel Res. 1989;241:146–65.

  10. 10.

    Weber BG, Brunner C. The treatment of nonunions without electrical stimulation. Clin Orthop Rel Res. 1981;161:24–32.

  11. 11.

    Hausman MR, Schaffler MB, Majeska RJ. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone. 2001;29:560–4.

  12. 12.

    Fassbender M, Strobel C, Rauhe JS, Bergmann C, Schmidmaier G, Wildemann B. Local inhibition of angiogenesis results in an atrophic non-union in a rat osteotomy model. Eur Cells Mater. 2011;22:1–11.

  13. 13.

    Gaston MS, Simpson AH. Inhibition of fracture healing. J Bone Joint Surg. 2007;89:1553–60.

  14. 14.

    Eckardt H, Ding M, Lind M, Hansen ES, Christensen KS, Hvid I. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg Br. 2005;87:1434–8.

  15. 15.

    Behr B, Tang C, Germann G, Longaker MT, Quarto N. Locally applied vascular endothelial growth factor A increases the osteogenic healing capacity of human adipose-derived stem cells by promoting osteogenic and endothelial differentiation. Stem Cells. 2011;29:286–96.

  16. 16.

    Li R, Stewart DJ, Schroeder HP, Mackinnon ES, Schemitsch EH. Effect of cell-based VEGF gene therapy on healing of a segmental bone defect. J Orthop Res. 2009;27:8–14.

  17. 17.

    Reed A, Joyner CJ, Brownlow HC, Simpson AH. Human atrophic fracture non-unions are not avascular. J Orthop Res. 2001;20:593–9.

  18. 18.

    Reed A, Joyner CJ, Isefuku S, Brownlow HC, Simpson AH. Vascularity in a new model of atrophic nonunion. J Bone Joint Surg. 2003;85:604–10.

  19. 19.

    Brownlow HC, Reed A, Hamish A, Simpson RW. The vascularity of atrophic non-unions. Injury. 2002;33:145–50.

  20. 20.

    Garcia P, Pieruschka A, Klein M, Tami A, Histing T, Jh H, Scheuer C, Pohlemann T. Temporal and spatial vascularization patterns of unions and nonunions: role of vascular endothelial growth factor and bone morphogenetic proteins. JBJS. 2012;94:49–58.

  21. 21.

    Schira J, Schulte M, Dobele C, Wallner C, Abraham S, Daigeler A, Kneser U, Lehnhardt M, Behr B. Human scaphoid non-unions exhibit increased osteoclast activity compared to adjacent cancellous bone. J Cell Mol Med. 2015;19:2842–50.

  22. 22.

    Brownlow HC, Reed A, Simpson AH. Growth factor expression during the development of atrophic non-union. Injury Int J Care Injured. 2001;32:519–24.

  23. 23.

    Kwong FNK, Hoyland JA, Freemont AJ, Evans CH. Altered relative expression of BMPs and BMP inhibitors in cartilaginous areas of human fractures progressing towards nonunion. J Orthop Res. 2009;27:752–7.

  24. 24.

    Lienau J, Schmidt-Bleek K, Peters A, Weber H, Bail HJ, Duda G, Perka C, Schell H. Insight into the molecular pathophysiology of delayed bone healing in a sheep model. Tissue Eng Part A. 2010;16:191–9.

  25. 25.

    Niikura T, Hak DJ, Reddi AH. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res. 2006;24:1463–71.

  26. 26.

    Garcia P, Holstein JH, Maier S, Schaumloffel H, Al-Marrawi F, Hannig M, Pohlemann T, Menger MD. Development of a reliable non-union model in mice. J Surg Res. 2008;147:84–91.

  27. 27.

    Chen H, Ji X, She F, Gao Y, Tang P. miR-628-3p regulates osteoblast differentiation by targeting RUNX2: possible role in atrophic non-union. Int J Mol Med. 2017;39:279–86.

  28. 28.

    Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001;79:243–53.

  29. 29.

    Zhang C, Dou CE, Xu J, Dong S. DC-STAMP, the key fusion-mediating molecule in osteoclastogenesis. J Cell Physiol. 2014;229:1330–5.

  30. 30.

    Laird RK, Pavlos NJ, Xu J, Brankov B, White B, Fan Y, Papadimitriou JM, Wood DJ, Zheng MH. Bone allograft non-union is related to excessive osteoclastic bone resorption: a sheep model study. Histol Histopathol. 2006;21:1277–85.

  31. 31.

    Hess K, Ushmorov A, Fiedler J, Brenner RE, Wirth T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone. 2009;45:367–76.

  32. 32.

    Briolay A, Lencel P, Bessueille L, Caverzasio J, Buchet R, Magne D. Autocrine stimulation of osteoblast activity by Wnt5a in response to TNF-alpha in human mesenchymal stem cells. Biochem Biophys Res Commun. 2013;430:1072–7.

  33. 33.

    Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15:757–65.

  34. 34.

    Timmen M, Hidding H, Wieskotter B, Baum W, Pap T, Raschke MJ, Schett G, Zwerina J, Stange R. Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation. BMC Musculoskelet Disord. 2014;15:184.

  35. 35.

    Jones D, Glimcher LH, Aliprantis AO. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest. 2011;121:2534–42.

  36. 36.

    Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5:667–76.

  37. 37.

    Takayanagi H. New developments in osteoimmunology. Nat Rev Rheumatol. 2012;8:684–9.

  38. 38.

    Kayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S, Leone CW, Morgan EF, Gerstenfeld LC, Einhorn TA, Graves DT. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007;22:560–8.

  39. 39.

    Li P, Schwarz EM, O’Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNF-alpha-mediated increase in CD11bhi osteoclast precursors but is essential for mature osteoclast formation in TNF-alpha-mediated inflammatory arthritis. J Bone Miner Res. 2004;19:207–13.

  40. 40.

    Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1992;35:1170–8.

  41. 41.

    Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991;34:1125–32.

  42. 42.

    Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med. 2008;14:245–53.

  43. 43.

    Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol. 1998;110:47–51.

  44. 44.

    Zimmermann G, Henle P, Küsswetter M, Moghaddam A, Wentzensen A, Richter W, Weiss S. TGF-β1 as a marker of delayed fracture healing. Bone. 2005;36:779–85.

  45. 45.

    Arumugam B, Vairamani M, Partridge NC, Selvamurugan N. Characterization of Runx2 phosphorylation sites required for TGF-β1-mediated stimulation of matrix metalloproteinase-13 expression in osteoblastic cells. J Cell Physiol. 2018;233:1082–94.

  46. 46.

    Aref-Eshghi E, Liu M, Harper PE, Doré J, Martin G, Furey A, Green R, Rahman P, Zhai G. Overexpression of MMP13 in human osteoarthritic cartilage is associated with the SMAD-independent TGF-β signalling pathway. Arthritis Res Ther. 2015;17:1–8.

  47. 47.

    Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA. Altered fracture repair in the absence of MMP9. Development. 2003;130:4123–33.

  48. 48.

    Kosaki N, Takaishi H, Kamekura S, Kimura T, Okada Y, Minqi L, Amizuka N, Chung U-I, Nakamura K, Kawaguchi H, et al. Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. Biochem Biophys Res Commun. 2007;354:846–51.

  49. 49.

    Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Wang J, Robinson S, Guo XE, Lund T, et al. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest. 2016;126:1759–72.

  50. 50.

    Shah M, Huang D, Blick T, Connor A, Reiter LA, Hardink JR, Lynch CC, Waltham M, Thompson EW. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE. 2012;7:e29615.

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by a grant of AFOR.

Author information

JW, SS, SD, and MD did all the experiments and BB, JW, FR, MD, CW, JH, SS, SD, HJ, MB, ML interpreted data and contributed to research design. All accepted the final version of the manuscript. All authors read and approved the final manuscript.

Correspondence to Johannes M. Wagner.

Ethics declarations

Ethics approval and consent to participate

All experiments were performed in adherence to the National Institute of Health guidelines for the use of experimental animals and after approval by the German legislation. The protocol was approved by the LANUV (NRW, Germany; Permit-Number: 84-02.04.2016.A034).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wagner, J.M., Schmidt, S.V., Dadras, M. et al. Inflammatory processes and elevated osteoclast activity chaperon atrophic non-union establishment in a murine model. J Transl Med 17, 416 (2019) doi:10.1186/s12967-019-02171-4

Download citation

Keywords

  • Atrophic non-union
  • Osteoclasts
  • Bone regeneration
  • Osteoimmunology